[go: up one dir, main page]

MA31857B1 - N-phenyl-pyrrolidinylmethylpyrrolidine-amides substitues et utilisation therapeutique de ceux -ci - Google Patents

N-phenyl-pyrrolidinylmethylpyrrolidine-amides substitues et utilisation therapeutique de ceux -ci

Info

Publication number
MA31857B1
MA31857B1 MA32849A MA32849A MA31857B1 MA 31857 B1 MA31857 B1 MA 31857B1 MA 32849 A MA32849 A MA 32849A MA 32849 A MA32849 A MA 32849A MA 31857 B1 MA31857 B1 MA 31857B1
Authority
MA
Morocco
Prior art keywords
phenyl
substituted
pyrrolidinylmethylpyrrolidine
amides
therapeutic use
Prior art date
Application number
MA32849A
Other languages
English (en)
Inventor
Werngard Czechtizky
Zhongli Gao
William J Hurst
Lothar Schwink
Siegfried Stengelin
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA31857B1 publication Critical patent/MA31857B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE SÉRIE D'AMIDES DE N-PHÉNYL-PYRROLIDINYLMÉTHYLPYRROLIDINE SUBSTITUÉS DE FORMULE (I) TELS QUE DÉCRITS ICI. PLUS PARTICULIÈREMENT, LES COMPOSÉS DE LA PRÉSENTE INVENTION SONT DES MODULATEURS DES RÉCEPTEURS H3 ET SONT, PAR CONSÉQUENT, UTILES COMME AGENTS PHARMACEUTIQUES, EN PARTICULIER DANS LE TRAITEMENT ET/OU LA PRÉVENTION D'UNE VARIÉTÉ DE MALADIES MODULÉES PAR DES RÉCEPTEURS H3 COMPRENANT DES MALADIES ASSOCIÉES AVEC LE SYSTÈME NERVEUX CENTRAL. DE PLUS, CETTE INVENTION DÉCRIT ÉGALEMENT DES PROCÉDÉS DE PRÉPARATION D'AMIDES DE N-PHÉNYL-PYRROLIDINYLMÉTHYLPYRROLIDINE SUBSTITUÉS ET D'INTERMÉDIAIRES DE CEUX-CI.
MA32849A 2007-10-17 2010-05-17 N-phenyl-pyrrolidinylmethylpyrrolidine-amides substitues et utilisation therapeutique de ceux -ci MA31857B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98060207P 2007-10-17 2007-10-17

Publications (1)

Publication Number Publication Date
MA31857B1 true MA31857B1 (fr) 2010-11-01

Family

ID=40137955

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32849A MA31857B1 (fr) 2007-10-17 2010-05-17 N-phenyl-pyrrolidinylmethylpyrrolidine-amides substitues et utilisation therapeutique de ceux -ci

Country Status (19)

Country Link
US (1) US8227504B2 (fr)
EP (1) EP2205558B1 (fr)
JP (1) JP5377504B2 (fr)
KR (1) KR20100092443A (fr)
CN (1) CN101903342B (fr)
AU (1) AU2008312636B2 (fr)
BR (1) BRPI0818766A2 (fr)
CA (1) CA2702834C (fr)
DK (1) DK2205558T3 (fr)
ES (1) ES2392122T3 (fr)
IL (1) IL205000A0 (fr)
MA (1) MA31857B1 (fr)
MX (1) MX2010004003A (fr)
MY (1) MY150210A (fr)
NZ (1) NZ584691A (fr)
PT (1) PT2205558E (fr)
RU (1) RU2477721C2 (fr)
WO (1) WO2009052063A1 (fr)
ZA (1) ZA201002113B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20110953T1 (hr) 2007-10-17 2012-01-31 Sanofi Supstituirani n-fenilbipirolidinkarboksamidi i njihova upotreba u terapiji
PL2215058T3 (pl) 2007-10-17 2012-04-30 Sanofi Sa Podstawione N-fenylo-bipirolidynomoczniki oraz ich zastosowanie terapeutyczne
PT2212283E (pt) 2007-10-17 2011-11-03 Sanofi Sa Carboxamidas de n-fenil-bipirrolidina substituídas e sua utilização terapêutica
AR074466A1 (es) * 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
AR074467A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras.
JP5833105B2 (ja) 2010-05-11 2015-12-16 サノフイ 置換ｎ−ヘテロアリールスピロラクタムビピロリジン類、その製造及び治療的使用
EP2569303A1 (fr) 2010-05-11 2013-03-20 Sanofi Dérivés n-alkyl et n-acyl tétrahydro-isoquinoline substitués, procédé de préparation et application thérapeutiques associés
EP2569280B1 (fr) 2010-05-11 2015-02-25 Sanofi Phényl-cycloalkyl-pyrrolidine- (pipéridine-) spirolactames et amides substituées, leur préparation et utilisation thérapeutique
TW201206910A (en) * 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof
JP2013526529A (ja) 2010-05-11 2013-06-24 サノフイ 置換されたｎ−ヘテロアリールビピロリジンカルボキサミド、その製造及び治療上の使用
EP2569305B1 (fr) 2010-05-11 2015-04-08 Sanofi Dérivés de n-hétéroaryl tétrahydro-isoquinolines substituées, procédé de préparation et usage thérapeutique associés
RU2562461C1 (ru) * 2014-04-30 2015-09-10 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) Спин-меченое производное кинуренина и способ его получения

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
AU2003287206A1 (en) * 2002-10-23 2004-05-13 Janssen Pharmaceutica, N.V. Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
MX2007011374A (es) * 2005-03-17 2007-11-23 Lilly Co Eli Derivados de pirrolidina como antagonistas del receptor histamina h3.
EP1868991B1 (fr) * 2005-04-01 2014-07-30 Eli Lilly And Company Agents agissant sur le recepteur h3 de l'histamine, leur preparation et leurs utilisations therapeutiques
US8008296B2 (en) * 2005-07-01 2011-08-30 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
WO2007048595A1 (fr) * 2005-10-27 2007-05-03 Ucb Pharma, S.A. Composés comprenant un lactame ou un groupement dérivé de lactame, procedes de fabrication de ceux-ci, et leurs utilisations
RU2008136898A (ru) * 2006-02-15 2010-03-20 Санофи-Авентис (Fr) Азациклил-замещенные арилдигидроизохинолиноны, способ их получения и их применение в качестве лекарственных средств
HRP20110953T1 (hr) 2007-10-17 2012-01-31 Sanofi Supstituirani n-fenilbipirolidinkarboksamidi i njihova upotreba u terapiji
PL2215058T3 (pl) 2007-10-17 2012-04-30 Sanofi Sa Podstawione N-fenylo-bipirolidynomoczniki oraz ich zastosowanie terapeutyczne
PT2212283E (pt) 2007-10-17 2011-11-03 Sanofi Sa Carboxamidas de n-fenil-bipirrolidina substituídas e sua utilização terapêutica

Also Published As

Publication number Publication date
KR20100092443A (ko) 2010-08-20
AU2008312636B2 (en) 2013-03-14
CN101903342A (zh) 2010-12-01
DK2205558T3 (da) 2012-11-05
PT2205558E (pt) 2012-11-02
BRPI0818766A2 (pt) 2015-04-14
CA2702834C (fr) 2013-01-15
US20100173898A1 (en) 2010-07-08
CN101903342B (zh) 2012-11-21
JP5377504B2 (ja) 2013-12-25
EP2205558B1 (fr) 2012-07-25
AU2008312636A1 (en) 2009-04-23
RU2010119530A (ru) 2011-11-27
ES2392122T3 (es) 2012-12-04
HK1146055A1 (en) 2011-05-13
EP2205558A1 (fr) 2010-07-14
NZ584691A (en) 2011-09-30
ZA201002113B (en) 2010-12-29
WO2009052063A1 (fr) 2009-04-23
US8227504B2 (en) 2012-07-24
RU2477721C2 (ru) 2013-03-20
IL205000A0 (en) 2010-11-30
JP2011500694A (ja) 2011-01-06
MX2010004003A (es) 2010-04-30
MY150210A (en) 2013-12-13
CA2702834A1 (fr) 2009-04-23

Similar Documents

Publication Publication Date Title
MA31857B1 (fr) N-phenyl-pyrrolidinylmethylpyrrolidine-amides substitues et utilisation therapeutique de ceux -ci
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA30207B1 (fr) Modulateurs des recepteurs de la progesterone a base d'indole sulfonamide
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
MA32257B1 (fr) Hydroxymethyl pyrrolidines comme agonistes des recepteurs beta-3- adrenergiques.
MA27347A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
MA29444B1 (fr) Antagonistes npy, preparation et utilisations
MA30411B1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
TNSN08099A1 (fr) 1-h-imidazopyridines a substituant hydroxy et procedes
MA30084B1 (fr) Triazolopyridazines en tant que modulateurs de la tyrosine kinase
MA47447A (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA31858B1 (fr) N-phenyl-bipyrrolidine-carboxamides substitues et utilisation therapeutique de ceux-ci
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
TNSN05317A1 (fr) Ligands des recepteurs de cannabinoides et leurs utilisations
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA32627B1 (fr) Derive d'amides heteroaryliques et leur utilisation comme activateurs de glucokinase
MA27692A1 (fr) Composes derives de benzoxazinone, leur preparation et utilisation comme medicaments
MA32705B1 (fr) Composes cycliques spiro-tetracycliques utiles en tant que modulateurs de la beta-secretase et leurs procedes d'utilisation
MA29805B1 (fr) Derives de phenyl-1.2.4-oxadiazolone, leurs procedes de preparation et leur utilisation comme produits pharmaceutiques
MA31766B1 (fr) Composés organiques
MA27428A1 (fr) Derives de pyrimidine et leur utilisation en tant que modulateurs cb2
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA32131B1 (fr) Antagonistes aminoalkylbiphényle n, n' disubstitués des récepteurs d2 de la prostaglandine